spacer
home > ict > winter 2009 > chain reactions
PUBLICATIONS
International Clinical Trials

Chain Reactions

 

Management of cold chain clinical supplies presents sponsor companies with significant logistical challenges, especially considering the global nature of distribution to many less developed regions and emerging markets. When investigational products are shipped, supplies are subject to various factors which may influence the way in which temperature-controlled shipping systems may operate. These variables include a myriad of external temperature ranges, supply routes, transit time, and availability of stability data and people.

The nature of clinical trial shipments means that they are exposed to more risks than commercial shipments due to their urgency, diverse destinations, shipping methodologies or routes and variable shipment quantities. However, the goal still remains to ensure a consistent flow of material arriving at the site in a condition which is fit for its intended use.

When contemplating cold chain logistics, there are a number of elements to take into consideration:

  • Packaging for maintenance of temperature control – active and passive shipping systems
  • Use of monitoring devices
  • Courier selection and transit time
  • Planning for deviations

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Jonathan Calderwood is the Global Marketing Manager for Almac Clinical Services (Almac Group). He was educated in Queen’s University, gaining a BSc in Biochemistry, and he holds a Post Graduate Diploma in Computer Science and in Marketing, and is a member of the Chartered Institute of Marketing. Jonathan has extensive experience in clinical trial supply production and project management, as well as in the business development field.

spacer
Jonathan Calderwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service

PRA Health Sciences, Inc. announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement